Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the IPIG PNH Registry

Active, not recruiting

Conditions: Hemoglobinuria, Paroxysmal

Interventions: Drug: Iptacopan

First Posted Date: 2025-03-30

Last Posted Date: 2025-05-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT06903234

Locations: 🇨🇭
Novartis Investigative Site, Basel, Switzerland

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

First Posted Date: 2025-03-27

Last Posted Date: 2025-03-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 155

Registration Number: NCT06897657

Locations: 🇺🇸
Novartis, East Hanover, New Jersey, United States

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Phase 2

Recruiting

Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions: Drug: AAA617

First Posted Date: 2025-03-25

Last Posted Date: 2025-06-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 420

Registration Number: NCT06894511

Locations: 🇺🇸
Urology Cancer Center PC, Omaha, Nebraska, United States

Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.

Recruiting

Conditions: Hidradenitis Suppurativa

First Posted Date: 2025-03-25

Last Posted Date: 2025-04-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT06785675

Locations: 🇦🇪
Novartis Investigative Site, Sharjah, United Arab Emirates

Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

Phase 1

Not yet recruiting

Conditions: Prostate Cancer

Interventions: Drug: AAA602
Drug: AAA802
Drug: Gallium (68Ga) gozetotide
Drug: Piflufolastat (18F)
Drug: Flotufolastat F 18
Drug: 18F-PSMA-1007

First Posted Date: 2025-03-18

Last Posted Date: 2025-05-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 228

Registration Number: NCT06881823

Pelacarsen Roll-over Extension Program

Phase 3

Not yet recruiting

Conditions: Atherosclerotic Cardiovascular Disease

Interventions: Drug: Pelacarsen (TQJ230)

First Posted Date: 2025-03-14

Last Posted Date: 2025-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 600

Registration Number: NCT06875973

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Phase 3

Recruiting

Conditions: Relapsing Multiple Sclerosis (RMS)

Interventions: Biological: Ofatumumab approved dose
Biological: Ofatumumab new dose

First Posted Date: 2025-03-11

Last Posted Date: 2025-06-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 180

Registration Number: NCT06869785

Locations: 🇺🇸
Alabama Neurology Associates PC, Birmingham, Alabama, United States
🇺🇸
Xenoscience Inc, Phoenix, Arizona, United States
🇺🇸
Ctr for Neurology and Spine, Phoenix, Arizona, United States

and more 35 locations

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

Phase 2

Recruiting

Conditions: Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)

Interventions: Drug: Remibrutinib
Drug: Placebo

First Posted Date: 2025-03-10

Last Posted Date: 2025-05-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 44

Registration Number: NCT06865651

Locations: 🇺🇸
Ziaderm Research LLC, North Miami Beach, Florida, United States
🇺🇸
Endeavor Health, Glenview, Illinois, United States

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

Phase 2

Recruiting

Conditions: ANCA Associated Vasculitis (AAV)

Interventions: Biological: Rapcabtagene autoleucel
Other: Active Comparator
Drug: Glucocorticoids

First Posted Date: 2025-03-10

Last Posted Date: 2025-06-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 126

Registration Number: NCT06868290

Locations: 🇺🇸
Northwestern Memorial Hospital, Evanston, Illinois, United States
🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States
🇨🇭
Novartis Investigative Site, Bern, Switzerland

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Phase 3

Recruiting

Conditions: Chronic Spontaneous Urticaria (CSU)

Interventions: Drug: Remibrutinib
Drug: Remibrutinib matching placebo
Drug: Placebo solution for injection
Drug: Dupilumab

First Posted Date: 2025-03-10

Last Posted Date: 2025-07-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 400

Registration Number: NCT06868212

Locations: 🇺🇸
Conquest Research, Winter Park, Florida, United States
🇺🇸
Allergy and Asthma Specialist P S C, Owensboro, Kentucky, United States
🇺🇸
Arlington Center for Dermatology, Arlington, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy